Crescent Biopharma, Inc.
CBIO
$14.47
-$0.23-1.57%
NASDAQ
| 06/30/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 148.72% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 47.84% | ||||
| Operating Income | -47.84% | ||||
| Income Before Tax | -43.85% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -43.85% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -43.85% | ||||
| EBIT | -47.84% | ||||
| EBITDA | -- | ||||
| EPS Basic | 71.44% | ||||
| Normalized Basic EPS | 69.95% | ||||
| EPS Diluted | 71.44% | ||||
| Normalized Diluted EPS | 69.95% | ||||
| Average Basic Shares Outstanding | 378.64% | ||||
| Average Diluted Shares Outstanding | 378.64% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||